SSE Ticker: 600252

Guangxi Wuzhou Zhongheng Group Co., Ltd.

中恒集团

Authorized Representative: 焦明

Board: Main A

Industry Classification: Manufacturing

Zhongheng Group: The company's pharmaceutical research and development direction is mainly concentrated in the field of traditional Chinese medicine research and development, mainly in the fields of cardiovascular and cerebrovascular, classic traditional Chinese medicine and other fields

Post date May 17, 2022 — 09:30 Post Lock

Zhongheng Group: At present, the company's lung cancer drug anhydrous dulcitol for injection is in the process of listing.

Post date May 17, 2022 — 09:30 Post Lock

Zhongheng Group: The company will adjust its sales strategy in a timely manner and drive the volume of retail products from multiple dimensions.

Post date May 17, 2022 — 09:30 Post Lock

Zhongheng Group: The company's drugs have not entered the scope of centralized procurement in Guangdong, which has a certain impact on the company's operations.

Post date May 17, 2022 — 09:28 Post Lock

Zhongheng Group: The company's investment in the construction of a pharmaceutical intelligent manufacturing valley is based on sufficient research and demonstration, and investment decisions are made prudently and scientifically.

Post date May 17, 2022 — 09:27 Post Lock

Zhongheng Group: Standardized corporate governance, all production and operation conditions are normal.

Post date May 17, 2022 — 09:26 Post Lock

Zhongheng Group: Researches related to the upgrading of Xueshuantong (lyophilized) technology for injection have been completed.

Post date May 17, 2022 — 09:25 Post Lock

Zhongheng Group: The company has formed an industrial layout of Chinese patent medicines, APIs, chemical medicines, generic medicines, biological medicines, pharmaceutical distribution, and daily chemical supplies

Post date May 17, 2022 — 09:25 Post Lock

Zhongheng Group: The company's epidemic prevention products are normally sold externally. At present, the company's masks and other protective products account for a small proportion of the company's consolidated revenue and profits.

Post date May 17, 2022 — 09:25 Post Lock

Zhongheng Group: Researches related to the upgrading of Xueshuantong (lyophilized) technology for injection have been completed.

Post date May 17, 2022 — 09:25 Post Lock

Zhongheng Group: The company's epidemic prevention products are normally sold externally. At present, the company's masks and other protective products account for a small proportion of the company's consolidated revenue and profits.

Post date May 17, 2022 — 09:25 Post Lock

Zhongheng Group: Corporate Governance Standardizes, Production and Operation are All Normal_Oriental Fortune Net

Post date May 17, 2022 — 09:24 Post Lock

Zhongheng Group: The company's investment in the construction of a pharmaceutical intelligent manufacturing valley is a prudent and scientific investment decision based on sufficient research and demonstration

Post date May 17, 2022 — 09:23 Post Lock

Zhongheng Group: The company's drugs have not entered the scope of Guangdong centralized procurement, which will have a certain impact on the company's operations

Post date May 17, 2022 — 09:22 Post Lock

Zhongheng Group: The company has no direct research investment in Chinese patent medicine for new coronary pneumonia for the time being

Post date May 17, 2022 — 09:21 Post Lock

Zhongheng Group: At present, the company's masks and other protective products account for a small proportion of the company's consolidated revenue and profits

Post date May 17, 2022 — 09:21 Post Lock

Intensive "tonic"! Refinancing actions of securities companies are frequent, and these things must be done

Post date May 13, 2022 — 15:01 Post Lock

Zhongheng Group's pharmaceutical R&D energy storage food performance has soared, and diversified operations are now effective

Post date May 7, 2022 — 14:03 Post Lock

What are the exclusive Chinese medicine concept stocks in 2022? Exclusive list and ranking of leading Chinese medicine stocks (stock code)

Post date May 2, 2022 — 11:17 Post Lock

Zhongheng Group announced the 2021 annual equity distribution plan to distribute 0.27 yuan in 10 distributions

Post date April 25, 2022 — 22:31 Post Lock

Want to see more data? Registered subscribers can see all the data.